Atsena touts one-year data for congenital eye disease therapy as it seeks partner for pivotal study
Atsena Therapeutics’ gene therapy improved vision in a handful of patients with certain mutations of Leber congenital amaurosis, a disorder that causes severe vision loss …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
